Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Moderna, planning big COVID-19 capacity upgrades, pledges 500M doses to COVAX
CVS assisting employers with on-site vaccine clinics through Return Ready platform
How new 'lung-on-a-chip' models from Harvard are advancing COVID-19 drug discovery
Glass half-full? Embattled AstraZeneca CEO Soriot defends COVID-19 vaccine
With supply timelines more certain, Novavax closes in on a COVID-19 vaccine deal with Europe: report
UPDATED Coronavirus tracker: Democratic Representatives urge payer CEOs to maintain COVID-19 care waivers
COVID-19 tracker: Pfizer vaccine under review for adolescents in Europe; Novavax nears EU supply deal
Private equity firm buys PTS to seize on COVID-19-fueled transformation of nanoparticle delivery

Featured Story

Moderna, planning big COVID-19 capacity upgrades, pledges 500M doses to COVAX

By Fraiser Kansteiner

Moderna recently unveiled a far-reaching manufacturing investment that could lift COVID-19 vaccine output to 3 billion doses in 2022. Now, it's pledging 500 million of those shots to COVAX, the equitable vaccine distribution scheme spearheaded by Gavi, CEPI and WHO.

CVS assisting employers with on-site vaccine clinics through Return Ready platform

By Paige Minemyer

CVS Health is now assisting employers with on-site COVID-19 vaccination clinics through its Return Ready platform.

How new 'lung-on-a-chip' models from Harvard are advancing COVID-19 drug discovery

By Arlene Weintraub

Pitting COVID-19 drug candidates against the virus in cell cultures doesn’t accurately predict how effective they’ll be in the human respiratory tract. Now more accurate models of the human lung airway are uncovering new treatment candidates. They include the antimalarial drug amodiaquine, which reduced viral load in animal models of the virus by 70%.

Glass half-full? Embattled AstraZeneca CEO Soriot defends COVID-19 vaccine

By Beth Snyder Bulik

As the weeks turn to months on AstraZeneca’s COVID-19 vaccine filing in the U.S., the big question is when? Its answer remains the same—soon. But with so many other shots available, why bother?

With supply timelines more certain, Novavax closes in on a COVID-19 vaccine deal with Europe: report

By Kevin Dunleavy

Novavax has told the European Union that it will be ready to send COVID-19 vaccine shipments to Europe before the end of the year. That could help the biotech strike a supply agreement for hundreds of millions of doses.

UPDATED Coronavirus tracker: Democratic Representatives urge payer CEOs to maintain COVID-19 care waivers

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

COVID-19 tracker: Pfizer vaccine under review for adolescents in Europe; Novavax nears EU supply deal

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

The European Medicines Agency said it's started an "accelerated assessment" of the Pfizer-BioNTech COVID-19 vaccine for people aged 12 to 15. Novavax is said to be nearing a finalized supply deal with the European Union for up to 200 million doses of the protein-based vaccine. And more headlines.

Private equity firm buys PTS to seize on COVID-19-fueled transformation of nanoparticle delivery

By Nick Paul Taylor

A private equity group has bought Polypeptide Therapeutic Solutions for its nanoparticle drug delivery technologies. Arcline Investment Management struck the deal in the belief the success of mRNA COVID-19 vaccines has permanently accelerated the rise of nanoparticle delivery.

COVID-19 Tracker